Growth Hormone Secretagogues: What the Human Evidence Shows

Three compounds in this site's library act on the growth hormone axis: CJC-1295, ipamorelin and tesamorelin. They are frequently discussed as interchangeable. Their evidence bases are not remotely comparable, and the pattern of difference is instructive well beyond this class.

They work by different routes

CJC-1295 and tesamorelin are GHRH receptor agonists: they act where growth hormone-releasing hormone acts, stimulating pituitary somatotrophs.

Ipamorelin is a ghrelin receptor (GHS-R1a) agonist — a different receptor, a different upstream signal, converging on the same downstream output.

All three raise growth hormone. That is the easy part, and it is where most consumer discussion of this class begins and ends.

The surrogate endpoint trap

Growth hormone and IGF-1 concentrations are surrogate endpoints. They are measurable, they respond reliably, and they are not what anyone actually wants.

The Phase 1 CJC-1295 data are a clean example of a well-executed surrogate study. Randomised, placebo-controlled, dose-ranging: a single injection raised plasma GH two- to ten-fold for six days or more and IGF-1 one-and-a-half to three-fold for nine to eleven days, with an estimated half-life of 5.8 to 8.1 days ^[1].

Those are solid pharmacological findings in healthy volunteers. They establish that the molecule does what it was designed to do. They say nothing about whether doing it helps anyone.

What happened when someone measured an outcome

Ipamorelin was taken into a trial with a clinical endpoint — recovery of gastrointestinal function after bowel resection — and the result is worth reading in full.

A multicentre, double-blind, placebo-controlled Phase 2 study randomised 117 patients. Median time from first dose to tolerating a standardised solid meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, p = 0.15. The investigators reported no significant differences across the key and secondary efficacy analyses, and noted that the compound was well tolerated ^[2].

The one that finished

Tesamorelin went through the full pathway and holds an FDA approval — for the reduction of excess abdominal fat in adults with HIV and lipodystrophy, and nothing else ^[3].

The label is worth reading as a document about this whole class, because it states what a regulator concluded after reviewing the complete dataset:

• Long-term cardiovascular safety has not been established.
• The drug is not indicated for weight loss management; its effect on weight is neutral.
• Contraindicated in active malignancy, because growth hormone is a growth factor.
• The effects of prolonged IGF-1 elevation are unknown, and monitoring is required.
• Increased risk of glucose intolerance and diabetes, with monitoring required.

Every one of those statements applies to the pharmacology, not merely to the product. Anyone evaluating an unapproved GHRH-class compound is looking at a molecule that shares the mechanism, without the label, without the monitoring, and without the data behind the warnings.

What the class evidence adds up to

| | Human PK/PD | Clinical endpoint trial | Result | Approved | | --- | --- | --- | --- | --- | | CJC-1295 | Yes, Phase 1 | No | — | No | | Ipamorelin | Yes | Yes, Phase 2 | Missed primary endpoint | No | | Tesamorelin | Yes | Yes, Phase 3 | Met endpoints in a narrow population | Yes, narrowly |

The compounds most heavily marketed are the ones lowest in that table. That is not a coincidence: a compound with an approval has a label, a price, a prescriber and a regulator. A compound without one has none of those constraints, and the marketing expands to fill the space where the evidence is not.